The goal of the Lymphoma Program's clinical research effort is to make the treatment of lymphoid malignancies more effective and specific, while also less toxic. Toward that goal, the program makes promising new therapies available to patients with a variety of lymphoid malignancies, in a carefully monitored setting, through clinical trials.
Current research focuses on targeting tumors with drugs directed against specific molecular targets in lymphoid malignancies, or with antibodies reactive against tumor cell surface proteins, alone or linked to radionucleotides. Another target of therapy is the tumor's "microenvironment" using inhibitors of angiogenesis (new blood vessel development) and stimulators of the immune response. Our team is also leading several clinical trials of CAR T-cell therapy for lymphoma.
Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.
Featured Clinical Trials
Trial 22-121: A phase 2 study of brentuximab vedotin plus nivolumab without stem cell consolidation in patients with relapsed classical Hodgkin lymphoma
Principal Investigator: Philippe Armand, MD, PhD
Trial 21-040: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab (AVO) in patients with relapsed/refractory and previously untreated mantle call lymphoma
Principal Investigator: Austin Kim, MD